Table 1.
Clinical characteristics of the SABR study population.
| Characteristic | Mean ± SD or No. (%) |
|---|---|
|
| |
| Age (years) | |
| Mean ± SD | 68.8 ± 7.9 |
| Sex | |
| Male | 44 (55%) |
| Female | 36 (45%) |
| Zubrod performance status | |
| 0 | 55 (69%) |
| 1 | 25 (31%) |
| Histology | |
| Squamous cell carcinoma | 13 (16%) |
| Adenocarcinoma | 63 (79%) |
| NSCLC, not otherwise specified | 4 (5%) |
| Tumor stage | |
| T1aN0M0 | 52 (65%) |
| T1bN0M0 | 28 (35%) |
| Tumor size, cm | |
| Mean ± SD | 1.83 ± 0.56 |
| Tumor site | |
| Left lower lobe | 10 (13%) |
| Left upper lobe | 18 (22%) |
| Right lower lobe | 11 (14%) |
| Right middle lobe | 3 (4%) |
| Right upper lobe | 38 (47%) |
| Tumor location | |
| Central | 26 (33%) |
| Peripheral | 54 (67%) |
| Baseline smoking status | |
| Current | 16 (20%) |
| Former | 50 (63%) |
| Never | 14 (18%) |
| Baseline FEV1 (% predicted) | |
| Mean ± SD | 85.8 ± 19.1 |
| Baseline FVC (% predicted) | |
| Mean ± SD | 94.4 ± 16.5 |
| Baseline DLCO (% predicted) | |
| Mean ± SD | 81.4 ± 16.9 |
Abbreviations: SABR, stereotactic ablative radiotherapy; SD, standard deviation; NSCLC, non-small cell lung cancer; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusion capacity of the lungs for carbon monoxide